HIV Coinfection Enhances Complement Activation during Sepsis

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 474-483

  Huson, Michaëla A M ^a,b,e   Wouters, Diana ^c,d   Van Mierlo, Gerard ^c,d   Grobusch, Martin P ^b,e,f   Zeerleder, Sacha S ^c,d   Van Der Poll, Tom ^a  

^a Center of Experimental and Molecular Medicine   (United States)

^b Division of Infectious Diseases Laboratory   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Sanquin Blood Supply   (United States)

^e German Center for Infection Research   (Gabon)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

complement system proteins; HIV; malaria; mannose binding lectin; sepsis

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3BC; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4BC; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GABON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MIDDLE AGED; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEPSIS; SIGNAL TRANSDUCTION; TREND STUDY; VIRUS LOAD; IMMUNOLOGY; MICROBIOLOGY; PATHOPHYSIOLOGY; VIROLOGY; YOUNG ADULT;

ADULT; COINFECTION; COMPLEMENT ACTIVATION; FEMALE; HIV INFECTIONS; HUMANS; MALARIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; YOUNG ADULT;

EID: 84939501089     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv074     Document Type: Article

References (48)

1. Paul S, Gilbert HM, ZiecheckW, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13:415-8.
2. Rosenberg AL, Seneff MG, Atiyeh L,Wagner R, Bojanowski L, Zimmerman JE. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 2001; 29:548-56.
3. Chiang HH, Hung CC, Lee CM, et al. Admissions to intensive care unit of HIV-infected patients in the era of highly active antiretroviral therapy: etiology and prognostic factors. Crit Care 2011; 15:R202.
4. Huson MA, Stolp SM, van der Poll T, Grobusch MP. Communityacquired bacterial bloodstream infections in HIV-infected patients: A systematic review. Clin Infect Dis 2014; 58:79-92.
5. Huson MA, Grobusch MP, van der Poll T. The effect of HIV infection on the host response to bacterial sepsis. Lancet Infect Dis 2015; 15: 95-108.
6. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-97.
7. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369:840-51.
8. Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol 2012; 946: 147-59.
9. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multiorgan failure. Clin Dev Immunol 2012; doi:10.1155/2012/962927.
10. Biryukov S, Stoute JA. Complement activation in malaria: friend or foe? Trends Mol Med 2014; 20:293-301.
11. Flateau C, Le Loup G, Pialoux G. Consequences of HIV infection on malaria and therapeutic implications: A systematic review. Lancet Infect Dis 2011; 11:541-56.
12. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-3.
13. Huson MA, Kalkman R, Stolp SM, et al. The impact of HIV on presentation and outcome of bacterial sepsis and other causes of acute febrile illness in Gabon. Infection 2015. In press.
14. Planche T, Krishna S, Kombila M, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 2001; 65:599-602.
15. Wolbink GJ, Bollen J, Baars JW, et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993; 163:67-76.
16. Brouwer N, Frakking FN, van deWetering MD, et al. Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J Immunol 2009; 183:3496-504.
17. Wouters D, Wiessenberg HD, Hart M, et al. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. J Immunol Methods 2005; 298:35-45.
18. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun 2006; 7:85-94.
19. Madsen HO, SatzML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998; 161: 3169-75.
20. Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannosebinding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 2008; 47:510-6.
21. Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991; 7:579-85.
22. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174: 1417-24.
23. Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120. Blood 1996; 87:2329-36.
24. Thieblemont N, Haeffner-Cavaillon N, Weiss L, Maillet F, Kazatchkine MD. Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses 1993; 9:229-33.
25. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993; 67:53-9.
26. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
27. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev 2013; 254:207-24.
28. Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, Jacobson BF. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010; 104:1228-34.
29. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103:1192-201.
30. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol 2005; 42:145-52.
31. Saarloos MN, Lint TF, Spear GT. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIVinfected cells. Clin Exp Immunol 1995; 99:189-95.
32. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993; 7:1307-13.
33. Solder BM, Schulz TF, Hengster P, et al. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Lett 1989; 22:135-45.
34. Marschang P, Gurtler L, Totsch M, et al. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS 1993; 7:903-10.
35. Datta PK, Rappaport J. HIV and complement: hijacking an immune defense. Biomed Pharmacother 2006; 60:561-8.
36. Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immunol 1995; 13:277-305.
37. Hazelzet JA, de Groot R, van Mierlo G, et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 1998; 66:5350-6.
38. Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003; 106:106-15.
39. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43.
40. Charchaflieh J,Wei J, Labaze G, et al. The role of complement system in septic shock. Clin Dev Immunol 2012; doi:10.1155/2012/407324.
41. Hack CE, Nuijens JH, Felt-Bersma RJ, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86:20-6.
42. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC. Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol 1993; 69:136-42.
43. Andaluz-Ojeda D, Iglesias V, Bobillo F, et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care 2011; 15: R243.
44. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-87.
45. Mrus JM, Braun L, Yi MS, Linde-ZwirbleWT, Johnston JA. Impact ofHIV/ AIDS on care and outcomes of severe sepsis. Crit Care 2005; 9:R623-30.
46. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for complement proteins C3 and C4: A practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 2004; 18:1-8.
47. Adegnika AA, Ramharter M, Agnandji ST, et al. Epidemiology of parasitic co-infections during pregnancy in Lambarene, Gabon. Trop Med Int Health 2010; 15:1204-9.
48. Mitchell GF. Effector cells, molecules and mechanisms in host-protective immunity to parasites. Immunology 1979; 38:209-23.